Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Small-Cell Lung Cancer and Mesothelioma

2020 Year in Review - Lung Cancer - Lung Cancer

Dr David Spigel reviews the results of key studies from 2020 on novel approaches to first- or second-line treatment of SCLC and mesothelioma with both existing and emerging agents.

Related Items
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Web Exclusives published on October 4, 2021 in Lung Cancer, ASCO Highlights
2021 Midyear Review: Non–Small-Cell Lung Cancer
2021 Midyear Review - Non–Small-Cell Lung Cancer published on August 11, 2021 in Lung Cancer
Exciting New Data Presented on NSCLC at AACR 2021
David Spigel, MD
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Combination Therapies and New Molecular Targets—Presentations from AACR 2021
David Spigel, MD
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer
Matthew S. Mattila, PharmD, BCPS, BCOP, Joel M. Lundberg, MD, FACP
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in Case Report, Lung Cancer
Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in FDA Updates, Lung Cancer
FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in FDA Updates, Lung Cancer
Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in FDA Updates, Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
GEOMETRY Mono-1 Results: Capmatinib for the Treatment of MET Exon 14–Mutated NSCLC
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.